Ian MacLachlan
Corporate Officer/Principal at New York Academy of Sciences
Profile
Ian MacLachlan was the founder of Protiva Biotherapeutics, Inc. which was founded in 2000, where he held the title of Chief Scientific Officer from 2000 to 2008.
He also currently holds positions as a Member at the New York Academy of Sciences, the American Society of Gene Therapy, and the Oligonucleotide Therapeutics Society, Inc. Dr. MacLachlan's former position was as the Chief Technical Officer & Executive VP at Arbutus Biopharma Corp.
from 2014 to 2014.
Dr. MacLachlan received his undergraduate and doctorate degrees from the University of Alberta.
Ian MacLachlan active positions
Companies | Position | Start |
---|---|---|
New York Academy of Sciences
New York Academy of Sciences Miscellaneous Commercial ServicesCommercial Services New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Corporate Officer/Principal | - |
American Society of Gene Therapy | Corporate Officer/Principal | - |
Former positions of Ian MacLachlan
Companies | Position | End |
---|---|---|
ARBUTUS BIOPHARMA CORPORATION | Chief Tech/Sci/R&D Officer | 2014-12-30 |
Protiva Biotherapeutics, Inc.
Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA. | Founder | 2008-12-01 |
Training of Ian MacLachlan
University of Alberta | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
Private companies | 4 |
---|---|
Protiva Biotherapeutics, Inc.
Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA. | Health Technology |
New York Academy of Sciences
New York Academy of Sciences Miscellaneous Commercial ServicesCommercial Services New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY. | Commercial Services |
American Society of Gene Therapy | |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Stock Market
- Insiders
- Ian MacLachlan